# FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels

Source: [Science-Based Medicine](https://sciencebasedmedicine.org/fda-adds-optic-neuropathy-warning-to-glp-1-ra-drug-labels/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fda-adds-optic-neuropathy-warning-to-glp-1-ra-drug-labels) · 2026-11-19 · Medicine
Page: https://themorning.science/story/fda-adds-optic-neuropathy-warning-to-glp-1-ra-drug-labels-c3e13fb0acd7fe4b
Kind: policy · Impact: medium

## In brief

- The FDA has added an optic neuropathy warning to the labels of GLP-1 receptor agonist (GLP-1 RA) drugs.
- Science-Based Medicine says a causal relationship between GLP-1 RAs and "eye stroke" remains tenuous.
- The same source describes the FDA's decision as reasonable.

## Why it matters

The label change reflects a regulatory decision made despite a causal link that is still described as tenuous, so readers should weigh the warning against the limited evidence behind it.

## Coverage

- [FDA Adds Optic Neuropathy Warning to GLP-1 RA Drug Labels](https://sciencebasedmedicine.org/fda-adds-optic-neuropathy-warning-to-glp-1-ra-drug-labels/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fda-adds-optic-neuropathy-warning-to-glp-1-ra-drug-labels) — Science-Based Medicine, 2026-11-19

Tags: glp-1, drug safety, optic neuropathy, fda, medication labels

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
